Reports
Reports
Sale
The global irritable bowel syndrome treatment market size attained a value of about USD 2.63 billion in 2023. The market is anticipated to grow at a CAGR of 10.1% during the forecast period of 2024-2032. The global irritable bowel syndrome treatment market share is anticipated to achieve a value of USD 6.27 billion by 2032.
The market is being driven by the increasing prevalence of target diseases and the expanded use of medicines for such diseases. The global market is being dominated by North America.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Irritable bowel syndrome is among the most prevalent functional disorders, with an approximate global prevalence of 10-15%. The actual cause of the symptoms is not known, and symptoms may arise from changes in the activity of the brain, nervous system, and the gut. This can affect the regular feeling and function of the bowel.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the industry can be divided into IBS-C and IBS-D.
IBS-C can be further divided into:
IBS-D is further segmented into:
The industry can be broadly categorised based on its applications into:
The EMR report looks into the regional markets of irritable bowel syndrome treatment like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Improved marketing of existing products in various regions is likely to boost the demand over the forecast period 2024-2032. The increasing Linzess adoption in the USA, Europe, as well as Japan, has contributed greatly to the growth of revenues. In January 2020, Linzess was approved in China, which is expected to improve the demand further.
IBS’ continually rising economic burden impacts the quality of jobs and results in higher healthcare costs. In addition, this increased awareness of the disease has, therefore, encouraged the growth of the global irritable bowel syndrome treatment industry. However, the high prevalence of anxiety and depression is expected to catalyse the growth of the demand for irritable bowel syndrome over the forecast period.
The report presents a detailed analysis of the following key players in the global irritable bowel syndrome treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Irritable Bowel Syndrome Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Irritable Bowel Syndrome Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Irritable Bowel Syndrome Epidemiology (2016-2031)
5.3 Europe Irritable Bowel Syndrome Epidemiology (2016-2031)
5.4 Asia-Pacific Irritable Bowel Syndrome Epidemiology (2016-2031)
5.5 Latin America Irritable Bowel Syndrome Epidemiology (2016-2031)
5.6 Middle East & Africa Irritable Bowel Syndrome Epidemiology (2016-2031)
6 Global Irritable Bowel Syndrome Treatment Market Overview
6.1 Global Irritable Bowel Syndrome Treatment Market Historical Value (2017-2023)
6.2 Global Irritable Bowel Syndrome Treatment Market Forecast Value (2024-2032)
7 Global Irritable Bowel Syndrome Treatment Market Landscape
7.1 Irritable Bowel Syndrome Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Irritable Bowel Syndrome Treatment: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Irritable Bowel Syndrome Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Irritable Bowel Syndrome Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Irritable Bowel Syndrome Treatment Market Segmentation
11.1 Global Irritable Bowel Syndrome Treatment Market by Type
11.1.1 Market Overview
11.1.2 IBS-C
11.1.2.1 IBS-C Market
11.1.2.2 Linzess/Constella
11.1.2.3 Amitiza
11.1.2.4 Others
11.1.3 IBS-D
11.1.3.1 Xifaxan
11.1.3.2 Viberz
11.1.3.3 Others
11.2 Global Irritable Bowel Syndrome Treatment Market by Application
11.2.1 Market Overview
11.2.2 Cardiology
11.2.3 Urology and Nephrology
11.2.4 Oncology
11.2.5 Gastroenterology
11.2.6 Others
11.3 Global Irritable Bowel Syndrome Treatment Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics and Research Laboratories
11.3.4 Others
11.4 Global Irritable Bowel Syndrome Treatment Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Irritable Bowel Syndrome Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Irritable Bowel Syndrome Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Irritable Bowel Syndrome Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Irritable Bowel Syndrome Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Irritable Bowel Syndrome Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Takeda Pharmaceutical Company Limited
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Astellas Pharma
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Ironwood Pharmaceuticals, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 AstraZeneca
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Sebela Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bausch Health
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Salix Pharmaceuticals
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Abbott Laboratories.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Services Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GlaxoSmithKline plc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ono Pharmaceutical Co., Ltd.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Pfizer Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 LEXICON PHARMACEUTICALS, INC
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Irritable Bowel Syndrome Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global irritable bowel syndrome treatment market attained a value of nearly USD 2.63 billion.
The market is projected to grow at a CAGR of 10.1% between 2024 and 2032.
The market is being driven by the rising prevalence of irritable bowel syndrome owing to changes in brain, nervous system, or the gut.
The market growth in the forecast period can be associated with the rising awareness of irritable bowel syndrome and the corresponding measures undertaken for effective treatment.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major types of irritable bowel syndrome treatment are IBS-C and IBS-D.
The significant applications of irritable bowel syndrome treatment include cardiology, urology and nephrology, oncology, and gastroenterology, among others.
The major players in the industry are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Synthetic Biologics, Inc., Bausch Health Companies Inc., and Ardelyx, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.